Genalyte is entering a pivotal stage, commercializing its breakthrough rapid-lab technology and opening the door for providers to be early adopters.

Genalyte’s system delivers full lab panels in under 30 minutes, with automation that eliminates the need for an on-site lab technician. The result is faster diagnoses, reduced costs, and increased revenue potential for providers.

With regulatory clearances in place and more tests on the way, Genalyte is ready to scale.

Why This Matters Now

• Series D Round in Motion: Genalyte is ramping manufacturing as part of its Series D raise.
• Provider Early Adopter Program: This is a unique opportunity for clinics, health systems, and specialty providers to gain access before wider rollout.
• Nonbinding LOIs Accepted: Providers can secure a place in the pipeline now without committing capital.

How to Get Involved

Seed Healthcare is inviting providers to express interest via our Provider Interest Form to capture early leads. Whether you run a primary care practice, urgent care center, or specialty clinic, this is your chance to integrate cutting-edge diagnostics directly into your workflow.

• Investors: This is a commercial inflection point, technology validated, market demand high, and a clear path to scale.
• Providers: Be among the first to bring this innovation to your patients.